| アイテムタイプ |
学術雑誌論文 / Journal Article(1) |
| 公開日 |
2026-02-10 |
| タイトル |
|
|
タイトル |
Efficacy of Azacitidine Plus Venetoclax in Acute Myeloid Leukemia Transformed from Myelodysplastic Syndrome after Failure of Azacitidine Monotherapy |
|
言語 |
en |
| 言語 |
|
|
言語 |
eng |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
acute myeloid leukemia |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
azacitidine |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
myelodysplastic syndromes |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
venetoclax |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| 著者 |
Furumoto, Takafumi
Ando, Koji
Toriyama, Eo
Hata, Tomoko
Katsuoka, Shinichi
Nishimura, Saori
Ichinose, Masamitsu
Hashimoto, Miki
Fujioka, Machiko
Sakaki, Chika
Sakamoto, Hikaru
Chiwata, Masahiko
Kamijo, Rena
Kobayashi, Yuji
Kitanosono, Hideaki
Nakashima, Jun
Kato, Takeharu
Taguchi, Masataka
Horai, Makiko
Matsuo, Masatoshi
Makiyama, Junya
Itonaga, Hidehiro
Sato, Shinya
Baba, Maki
Sawayama, Yasushi
Takasaki, Yumi
Taguchi, Jun
Imanishi, Daisuke
Imaizumi, Yoshitaka
Kawaguchi, Yasuhisa
Tsushima, Hideki
Jo, Tatsuro
Yoshida, Shinichiro
Moriuchi, Yukiyoshi
Miyazaki, Yasushi
|
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Objective: Patients with acute myeloid leukemia (AML) transformed from myelodysplastic syndrome (MDS) have a poor prognosis, including those treated with azacitidine during the MDS phase; there is no standard for the care of these patients. Recently, azacitidine plus venetoclax (AZA/VEN) was reported to prolong the survival in treatment-naïve AML patients compared with AZA monotherapy. However, the results of AZA/VEN for AML transformed from MDS, particularly after AZA monotherapy, remain unclear. The present study therefore compared the clinical results of AZA/VEN treatment in these patients. Methods: Data from MDS patients diagnosed at 10 institutions in Nagasaki Prefecture were collected. Thereafter, patients with transformed AML following AZA monotherapy during the MDS phase were selected, and their treatment response and survival were analyzed. Results: The overall response (OR) rate, overall survival (OS), and event-free survival (EFS) were compared among patients treated with AZA/VEN (n=13), chemotherapy (intensive and low-intensity, n=35), AZA monotherapy (mAZA, n=15), and best supportive care (BSC, n=43) after AML transformation. The corresponding OR rates were 38.5%, 20.0%, and 6.7% for the AZA/VEN, chemotherapy, and mAZA groups, respectively (p=0.235). The respective median OS and EFS were 10.7 and 8.9 months for AZA/VEN, 3.2 and 2.0 months for chemotherapy, and 3.8 and 2.7 months for mAZA, and 1.7 months for BSC (OS only) (p=0.000023 for the OS and p=0.026 for the EFS), Conclusion: Our findings suggest the superiority of AZA/VEN for AML patients with transformation from MDS following AZA monotherapy. |
|
言語 |
en |
| 書誌情報 |
en : Internal Medicine
巻 65,
号 3,
p. 411-419,
発行日 2026-02-01
|
| 出版者 |
|
|
出版者 |
Japanese Society of Internal Medicine |
|
言語 |
en |
| 出版社別言語 |
|
|
言語 |
ja |
|
値 |
日本内科学会 |
| ISSN |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
0918-2918 |
| DOI |
|
|
関連タイプ |
isIdenticalTo |
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
https://doi.org/10.2169/internalmedicine.5312-25 |
| 権利 |
|
|
権利情報 |
© 2026 The Japanese Society of Internal Medicine. |
|
言語 |
en |
| 著者版フラグ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| 引用 |
|
|
内容記述タイプ |
Other |
|
内容記述 |
Internal Medicine, 65(3), pp.411-419; 2026 |
|
言語 |
en |
IM65_411.pdf (903 KB)
